Targeting 1α,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors

This publication has 13 references indexed in Scilit:

• Functions of 1α,25-dihydroxyvitamin D3 in mammary gland: from normal development to breast cancer
  Steroids, 2001
• Synergistic growth inhibition of prostate cancer cells by 1α,25 Dihydroxyvitamin D3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A
  Oncogene, 2001
• The anti-proliferative effects of 1α,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression
  Oncogene, 2000
• VDR-Alien: a novel, DNA-selective vitamin D3 receptor-corepressor partnership
  The FASEB Journal, 2000
• The Interaction of the Vitamin D Receptor with Nuclear Receptor Corepressors and Coactivators
  Biochemical and Biophysical Research Communications, 1998
• All-trans retinoic acid blocks the antiproliferative prodifferentiating actions of 1,25-Dihydroxyvitamin D3 in normal human keratinocytes
  Journal of Cellular Physiology, 1998
• Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
  Journal of Molecular Endocrinology, 1997
• Integrity of the 1,25-dihydroxyvitamin D3 receptor in bone, lung, and other cancers
  Molecular Carcinogenesis, 1997
• Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
  Molecular and Cellular Endocrinology, 1997
• Characterization of epithelial phenotypes in mortal and immortal human breast cells
  International Journal of Cancer, 1992